Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Liabilities and Shareholders Equity: 2023-2025

Historic Liabilities and Shareholders Equity for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $231.3 million.

  • Compass Therapeutics' Liabilities and Shareholders Equity rose 55.05% to $231.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $619.8 million, marking a year-over-year decrease of 0.48%. This contributed to the annual value of $140.4 million for FY2024, which is 10.50% down from last year.
  • Compass Therapeutics' Liabilities and Shareholders Equity amounted to $231.3 million in Q3 2025, which was up 98.17% from $116.7 million recorded in Q2 2025.
  • Compass Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $231.3 million for Q3 2025, and its period low was $116.7 million during Q2 2025.
  • For the 3-year period, Compass Therapeutics' Liabilities and Shareholders Equity averaged around $161.8 million, with its median value being $156.9 million (2023).
  • Over the last 5 years, Compass Therapeutics' Liabilities and Shareholders Equity had its largest YoY gain of 55.05% in 2025, and its largest YoY loss of 25.01% in 2025.
  • Over the past 3 years, Compass Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $156.9 million in 2023, then declined by 10.50% to $140.4 million in 2024, then spiked by 55.05% to $231.3 million in 2025.
  • Its last three reported values are $231.3 million in Q3 2025, $116.7 million for Q2 2025, and $131.5 million during Q1 2025.